WCLC Updates in Neoadjuvant Therapy for NSCLC
Experts in thoracic oncology discuss the role of single-agent immunotherapy as neoadjuvant therapy and comment on the viability of MPR [major pathologic response] as a surrogate endpoint for non–small cell lung cancer (NSCLC).
EP: 1.WCLC Updates in KRAS and Rare EGFR-Mutated NSCLC
EP: 2.WCLC Updates on the Emergence of ADCs in NSCLC
EP: 3.WCLC Updates in Immunotherapy for NSCLC
Now Viewing
EP: 4.WCLC Updates in Neoadjuvant Therapy for NSCLC
EP: 5.WCLC Updates in Locally Advanced NSCLC
EP: 6.WCLC Updates in Small Cell Lung Cancer
Data from the following clinical trial are discussed:
- PS01.05 - Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis
Related Videos
Related Content
